Skip to main content

Press Releases

Date Title
Toggle Summary Sienna Biopharmaceuticals Announces Results from First-in-Human Study of SNA-125 in Psoriasis and Continued Progression to Phase 2
-- Phase 1/2 study data of SNA-125 in atopic dermatitis on track to be released in fourth quarter of 2018 -- SNA-125 Phase 2 studies expected to begin in second half of 2019 WESTLAKE VILLAGE, Calif. , Aug. 27, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc.
Toggle Summary Sienna Biopharmaceuticals Reports Second Quarter 2018 Financial Results
WESTLAKE VILLAGE, Calif. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today reported the Company’s financial results for the second quarter of 2018. “We are pleased to report the results of a busy
Toggle Summary Sienna Biopharmaceuticals Appoints Finance Veteran, James M. Hindman, to Board of Directors
-- Hindman will chair Sienna’s Audit Committee WESTLAKE VILLAGE, Calif. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced that James (Jim) M. Hindman has been appointed to the Company’s
Toggle Summary Sienna Biopharmaceuticals Announces Pivotal Trials with SNA-001 in Acne Did Not Meet Primary and Secondary Endpoints
-- Results from independent pivotal trials with SNA-001 for the reduction of unwanted light-pigmented hair expected beginning in the fourth quarter of 2018 -- Sienna continues to advance robust multi-asset pipeline, including SNA-120 and SNA-125 -- Company will conduct conference call and webcast
Toggle Summary Sienna Biopharmaceuticals Successfully Completes Maximal Use Safety Study of SNA-120 in Patients with Itch Associated with Psoriasis
-- SNA-120, a new chemical entity derived from the company’s Topical by Design™ platform, was well tolerated with minimal to no detectable systemic exposure -- Vast majority of psoriasis patients suffer from itch, yet there are no FDA -approved topical therapies for chronic use in itch -- Phase 2b

SEC Filings


Webcast events that have already occurred are presented for historical purposes only and speak only as of the date thereof.

Stock Information

Copyright Nasdaq. Minimum 15 minutes delayed.

Refresh quote

Analyst Coverage

Firm Analyst
J.P. Morgan
Chris Schott
Ken Cacciatore
BMO Capital Markets
Gary Nachman

The analysts above have initiated and are maintaining formal research coverage of Sienna. Please note that any opinions, estimates or forecasts regarding Sienna’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Sienna or Sienna’s management. Sienna does not by reference above or distribution of same imply endorsement of or concurrence with any analyst’s opinions, estimates, forecasts, conclusions or recommendations. Sienna does not participate in the preparation of analysts’ reports and undertakes no obligation to verify or correct any information in such reports.

Transfer Agent

EQ Shareowner Services

IR Contact

Media Contact